Figure 3From: Retrospective analysis of the impact of platinum dose reduction and chemotherapy delays on the outcomes of stage III ovarian cancer patientsReasons for chemotherapy scheme modifications. Reason for every single platinum dose reduction and chemotherapy delay was established. The most common of them from most to least frequent were neutropenia, modifications with no objective medical reasons, renal disorders, anaemia, poor performance status, gastrointestinal (GI) symptoms and neuropathy.Back to article page